X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DR. REDDYS LAB - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DR. REDDYS LAB PANACEA BIOTECH/
DR. REDDYS LAB
 
P/E (TTM) x 178.1 30.0 593.6% View Chart
P/BV x 4.0 2.9 134.5% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PANACEA BIOTECH   DR. REDDYS LAB
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DR. REDDYS LAB
Mar-17
PANACEA BIOTECH/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1493,397 4.4%   
Low Rs822,560 3.2%   
Sales per share (Unadj.) Rs84.1856.5 9.8%  
Earnings per share (Unadj.) Rs-18.378.0 -23.5%  
Cash flow per share (Unadj.) Rs-6.7139.9 -4.8%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs83.7739.8 11.3%  
Shares outstanding (eoy) m61.25165.74 37.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.43.5 39.5%   
Avg P/E ratio x-6.338.2 -16.5%  
P/CF ratio (eoy) x-17.221.3 -81.0%  
Price / Book Value ratio x1.44.0 34.3%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m7,074493,632 1.4%   
No. of employees `0002.822.7 12.1%   
Total wages/salary Rs m1,44931,068 4.7%   
Avg. sales/employee Rs Th1,874.16,259.0 29.9%   
Avg. wages/employee Rs Th527.01,369.8 38.5%   
Avg. net profit/employee Rs Th-407.7569.7 -71.6%   
INCOME DATA
Net Sales Rs m5,154141,961 3.6%  
Other income Rs m1001,715 5.8%   
Total revenues Rs m5,254143,676 3.7%   
Gross profit Rs m-76624,722 -3.1%  
Depreciation Rs m71110,266 6.9%   
Interest Rs m1,503634 237.1%   
Profit before tax Rs m-2,88115,537 -18.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6349 -1.6%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m172,965 0.6%   
Profit after tax Rs m-1,12112,921 -8.7%  
Gross profit margin %-14.917.4 -85.4%  
Effective tax rate %-0.619.1 -3.1%   
Net profit margin %-21.89.1 -239.0%  
BALANCE SHEET DATA
Current assets Rs m3,81096,837 3.9%   
Current liabilities Rs m8,36584,199 9.9%   
Net working cap to sales %-88.48.9 -992.8%  
Current ratio x0.51.2 39.6%  
Inventory Days Days15673 212.2%  
Debtors Days Days6798 68.8%  
Net fixed assets Rs m14,480102,552 14.1%   
Share capital Rs m61829 7.4%   
"Free" reserves Rs m903121,792 0.7%   
Net worth Rs m5,127122,621 4.2%   
Long term debt Rs m5,8325,449 107.0%   
Total assets Rs m19,433218,165 8.9%  
Interest coverage x-0.925.5 -3.6%   
Debt to equity ratio x1.10 2,559.5%  
Sales to assets ratio x0.30.7 40.8%   
Return on assets %2.06.2 31.6%  
Return on equity %-21.910.5 -207.5%  
Return on capital %3.612.9 28.2%  
Exports to sales %24.554.6 44.9%   
Imports to sales %10.29.4 108.9%   
Exports (fob) Rs m1,26477,520 1.6%   
Imports (cif) Rs m52513,274 4.0%   
Fx inflow Rs m1,53981,670 1.9%   
Fx outflow Rs m94226,355 3.6%   
Net fx Rs m59755,315 1.1%   
CASH FLOW
From Operations Rs m59921,444 2.8%  
From Investments Rs m-438-18,404 2.4%  
From Financial Activity Rs m-303-3,692 8.2%  
Net Cashflow Rs m-141-1,144 12.4%  

Share Holding

Indian Promoters % 74.5 25.5 292.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.4 11.1%  
FIIs % 1.3 35.3 3.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 23.6 15.3 154.2%  
Shareholders   10,259 75,885 13.5%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 23, 2018 02:09 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS